Cargando…
Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has significantly improved the survival of MM patient...
Autores principales: | Monti, Matilde, Consoli, Francesca, Vescovi, Raffaella, Bugatti, Mattia, Vermi, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072514/ https://www.ncbi.nlm.nih.gov/pubmed/32054102 http://dx.doi.org/10.3390/cells9020417 |
Ejemplares similares
-
Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis
por: Monti, Matilde, et al.
Publicado: (2020) -
Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model
por: Rowland, Sarah L., et al.
Publicado: (2014) -
E-Cadherin Expression and Blunted Interferon Response in Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Lorenzi, Luisa, et al.
Publicado: (2021) -
A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
por: Consoli, Francesca, et al.
Publicado: (2020) -
Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo
por: Swiecki, Melissa, et al.
Publicado: (2011)